Literature DB >> 19207607

Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.

Tomohiko Hara1, Mutsuo Takahashi, Toshikazu Gondo, Kazuhiro Nagao, Chietaka Ohmi, Shigeru Sakano, Katsusuke Naito, Hideyasu Matsuyama.   

Abstract

OBJECTIVES: To determine candidates for bladder biopsies among Japanese primary non-muscle-invasive bladder cancer patients according to the risk of concomitant carcinoma in situ (CIS).
METHODS: Between January 1992 and August 2006, 173 primary non-muscle-invasive bladder cancer cases underwent transurethral resection of the bladder tumor with bladder biopsies for the detection of CIS. Correlations between biopsy results and preoperative/pathological features were retrospectively analyzed.
RESULTS: Positive cytology was statistically associated with the presence of concomitant CIS in multivariate analysis (P < 0.01). Abnormal cystoscopic appearance outside the tumor almost achieved statistical significance in multivariate analysis among preoperative factors (P = 0.06). In our series, one (12.5%) of eight low-risk, 18 (24.7%) of 73 intermediate-risk and 41 (59.4%) of 69 high-risk cases had CIS in normal-looking sites, respectively. In cases with a single papillary tumor and negative cytology, one of 16 (6.3%) had concomitant CIS in their biopsy specimens at the normal-looking sites.
CONCLUSIONS: All non-muscle-invasive bladder cancer patients with positive cytology are candidates for additional random biopsies. Targeted biopsies should be performed for all suspicious areas in the bladder mucosa. Random biopsies should be considered in cases with the macroscopic types of cancer for predicting intermediate- and high-risk cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19207607     DOI: 10.1111/j.1442-2042.2008.02241.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

2.  Clinical significance of random bladder biopsy in primary T1 bladder cancer.

Authors:  Masafumi Otsuka; Satoru Taguchi; Tohru Nakagawa; Teppei Morikawa; Shigekatsu Maekawa; Jimpei Miyakawa; Akihiko Matsumoto; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2018-03-08

3.  Preoperative pyuria predicts the presence of high-grade bladder carcinoma in patients with bladder tumors.

Authors:  Sławomir Poletajew; Dominika Gajewska; Krystian Kaczmarek; Wojciech Krajewski; Marcin Łykowski; Joanna Sondka-Migdalska; Michał Borowik; Paweł Buraczyński; Mateusz Dzięgała; Maciej Przudzik; Marcin Słojewski; Piotr Kryst
Journal:  Cent European J Urol       Date:  2020-12-03

4.  Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression.

Authors:  Wojciech Jóźwicki; Anna A Brożyna; Jerzy Siekiera
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

Review 5.  Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE).

Authors:  Nicholas E Power; Jonathan Izawa
Journal:  Bladder Cancer       Date:  2016-01-07

6.  Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.

Authors:  Piotr Zapała; Bartosz Dybowski; Sławomir Poletajew; Łukasz Białek; Andrzej Niewczas; Piotr Radziszewski
Journal:  World J Surg Oncol       Date:  2018-01-15       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.